Skip to main content

Table 2 Health outcomes in the treat-to-target (T2T) and usual care (UC) groups after two and three years of follow-up

From: Treating to the target of remission in early rheumatoid arthritis is cost-effective: results of the DREAM registry

  Two years Three years
  T2T (n=261) UC (n=213) UC from 2006 (n=69) T2T (n=127) UC (n=180) UC from 2006 (n=45)
DAS28, mean ± SD 2.4 ± 1.0 3.1 ± 1.3† 2.8 ± 1.1† 2.5 ± 1.0 3.1 ± 1.3† 2.7 ± 1.1
DAS28 level, n (%)       
 Remission (DAS28 < 2.6) 168 (64.4) 74 (34.7)† 33 (47.8)† 76 (59.8) 63 (35.0)† 25 (55.6)
 Low (2.6 ≤ DAS28 ≤ 3.2) 48 (18.4) 44 (20.7) 14 (20.3) 28 (22.0) 35 (19.4) 5 (11.1)
 Moderate (3.2 < DAS28 ≤ 5.1) 37 (14.2) 76 (35.7)† 19 (27.5)† 21 (16.5) 72 (40.0)† 14 (31.1)†
 High (DAS28 > 5.1) 8 (3.1) 19 (8.9)† 3 (4.3) 2 (1.6) 10 (5.6) 1 (2.2)
QALYs, median (IQR) 1.45 (1.24-1.55) (n=221) 1.39 (1.18-1.53) (n=143)† 1.44 (1.21-1.55) (n=47) 2.19 (1.81-2.34) (n=101) 2.04 (1.64-2.27) (n=106)† 1.95 (1.50-2.34) (n=18)
  1. Quality-adjusted life years (QALYs) were derived from the EuroQol-5D utility scores which were estimated from the Health Assessment Questionnaire (HAQ). QALYs could not be evaluated in all patients due to missing data in (items of) the HAQ.
  2. DAS28, Disease Activity Score in 28 joints; SD, standard deviation.
  3. † P < 0.05 for differences between groups (T2T versus UC).